Socio-demographic and clinical characteristic of MDR/XDRTB cases
| Characteristics | XDRTB (n=71), n (%) | MDRTB (n=1736), n (%) | Total (n=1807), n (%) |
| Male sex | 56 (78.9) | 1385 (79.8) | 1441 (79.7) |
| Age category, y | |||
| <30 | 8 (11.3) | 209 (12.0) | 217 (12.0) |
| 30–39 | 15 (21.1) | 361 (20.8) | 376 (20.8) |
| 40–49 | 19 (26.8) | 525 (30.2) | 544 (30.1) |
| 50–59 | 11 (15.5) | 404 (23.3) | 415 (23.0) |
| 60+ | 18 (25.4) | 237 (13.7) | 255 (14.1) |
| Country of birth | |||
| Lithuania | 66 (93.0) | 1657 (95.4) | 1723 (95.4) |
| Russia | 2 (2.8) | 36 (2.1) | 38 (2.1) |
| Belorussia | 2 (2.8) | 26 (1.5) | 28 (1.5) |
| Ukraine | 0 (0.0) | 9 (0.5) | 9 (0.5) |
| Other | 1 (1.4) | 8 (0.5) | 9 (0.5) |
| Rural living | 27 (38.0) | 597 (34.4) | 624 (34.5) |
| Contact with TB | 8 (11.3) | 81 (4.7) | 89 (4.9) |
| Smoking | 49 (69.0) | 1363 (78.5) | 1412 (78.1) |
| Alcohol* | |||
| Didn't use | 9 (12.7) | 188 (10.8) | 197 (10.9) |
| Sometimes | 19 (26.8) | 546 (31.5) | 565 (31.3) |
| Often | 33 (46.5) | 852 (49.1) | 885 (49.0) |
| Alcoholic | 10 (14.1) | 150 (8.6) | 160 (8.9) |
| Drug abuse | 1 (1.4) | 35 (2.0) | 36 (2.0) |
| Homelessness | 4 (5.6) | 134 (7.7) | 138 (7.6) |
| Unemployment | 62 (87.3) | 1480 (85.3) | 1542 (85.3) |
| Education | |||
| Less than primary | 9 (12.7) | 141 (8.1) | 150 (8.3) |
| Primary/secondary | 46 (64.8) | 1267 (73.0) | 1313 (72.7) |
| Tertiary | 16 (22.5) | 328 (18.9) | 344 (19.0) |
| HIV | |||
| Negative | 17 (23.9) | 268 (15.4) | 285 (15.8) |
| Positive | 0 (0.0) | 25 (1.4) | 25 (1.4) |
| Not tested | 54 (76.1) | 1443 (83.1) | 1497 (82.8) |
| Co-morbidity | 2 (2.8) | 42 (2.4) | 44 (2.4) |
| TB type | |||
| Pulmonary | 68 (95.8) | 1657 (95.4) | 1725 (95.5) |
| E/pulm | 0 (0.0) | 21 (1.2) | 21 (1.2) |
| Pulmonary and e/pulm | 3 (4.2) | 58 (3.3) | 61 (3.4) |
| Smear positivity | 55 (77.5) | 1343 (77.4) | 1398 (77.4) |
| Cavity | 47 (66.2) | 1172 (67.5) | 1219 (67.5) |
| Strain family | |||
| Non-Beijing | 6 (8.5) | 171 (9.9) | 177 (9.8) |
| Beijing | 10 (14.1) | 119 (6.9) | 129 (7.1) |
| Missing (not genotyped) | 55 (77.5) | 1446 (83.3) | 1501 (83.1) |
| SLDs used† | |||
| FQ | 29 (40.8) | 1077 (62.0) | 1106 (61.2) |
| INJ | 25 (35.2) | 605 (34.9) | 630 (34.9) |
| ETH/PT | 42 (59.2) | 1166 (67.2) | 1208 (66.9) |
| CS | 37 (52.1) | 735 (42.3) | 772 (42.7) |
| TRD | 2 (2.8) | 7 (0.4) | 9 (0.5) |
| PAS | 20 (28.2) | 231 (13.3) | 251 (13.9) |
| AMC | 0 (0.0) | 3 (0.2) | 3 (0.2) |
| THZ | 0 (0.0) | 1 (0.1) | 1 (0.1) |
| Combination of SLDs | |||
| No SLDs | 20 (28.2) | 425 (24.5) | 445 (24.6) |
| INJ only (group 2) | 0 (0.0) | 4 (0.2) | 4 (0.2) |
| FQ only (group 3) | 0 (0.0) | 18 (1.0) | 18 (1.0) |
| ETH/PT or PAS or TRD or CS only (group 4) | 9 (12.7) | 63 (3.6) | 72 (4.0) |
| Groups 2 and 3 | 0 (0.0) | 16 (0.9) | 16 (0.9) |
| Groups 2 and 4 | 11 (15.5) | 141 (8.1) | 152 (8.4) |
| Groups 3 and 4 | 14 (19.7) | 597 (34.4) | 611 (33.8) |
| Groups 2, 3 and 4 | 14 (19.7) | 443 (25.5) | 457 (25.3) |
| Groups 3, 4 and other | 0 (0.0) | 2 (0.1) | 2 (0.1) |
| Groups 2, 3, 4 and other | 0 (0.0) | 1 (0.1) | 1 (0.1) |
| ETH/PT only | 2 (2.8) | 25 (1.4) | 27 (1.5) |
| TRD or CS only | 1 (1.4) | 1 (0.1) | 2 (0.1) |
| Resistance pattern | |||
| INH+RIF only | 1513 (87.2) | 1513 (83.7) | |
| INH+RIF+Ofloxacin (‘Oflox’) | 30 (1.7) | 30 (1.7) | |
| INH+RIF+INJ | 124 (7.1) | 124 (6.9) | |
| INH+RIF+ETH/PT | 32 (1.8) | 32 (1.8) | |
| INH+RIF+Oflox+INJ (‘XDR’) | 43 (60.6) | 43 (2.4) | |
| INH+RIF+Oflox+INJ+ETH/PT (‘XDR’) | 28 (39.4) | 28 (1.5) | |
| INH+RIF+Oflox+ETH/PT | 24 (1.4) | 24 (1.3) | |
| INH+RIF+INJ+ETH/PT | 13 (0.7) | 13 (0.7) | |
↵* Alcohol excess was determined by physicians and reported as stated in patients' case histories according to nationally accepted breakdown categorisation.
↵† Some patients received more than one drug, so numbers do not add to total n.
AMC, Amoxicillin/clavulanate; CS, Cycloserine; e/pulm, extrapulmonary tuberculosis; ETH/PT, Ethionamide/Prothionamide; FQ, Fluoroquinolones; INH, isoniazid; INJ, injectables; MDR/XDRTB, multidrug- and extensively drug-resistant tuberculosis; PAS, P-aminosalicyclic acid; RIF, rifampicin; SLD, second-line drugs; THZ, Thiacetazone; TRD, Terizidone.